| Drug Name | GPCR-targeted Project 012 |
| Description |
Glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) that acts as the receptor for the incretin GLP-1, a peptide released to regulate insulin levels in response to food intake. High-affinity antibodies targeting GLP-1R are being developed for multiple indications such as type II diabetes and hypoglycemia. These antibodies are screened, humanized, and engineered through a proprietary GPCR monoclonal antibody development platform and showed either GLP-1R agonistic or antagonistic properties in early studies. |
| Target | Glucagon-like peptide-1 receptor (GLP-1R) |
| Drug Modality | Monoclonal antibody |
| Indication | Hypoglycemia; Type 2 diabetes mellitus |
| Product Category | Biologic |
| Mechanism of Action | GLP-1R agonists; GLP-1R antagonists |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |